Standard BioTools Inc. Overview
Pro stress-test →Standard BioTools develops, manufactures, and sells instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics globally. Key platforms include SomaScan for protein measurement, CyTOF for mass cytometry analysis, Hyperion for spatial biology, and Biomark X9 for genomics applications.
Strategic Profile
Pro stress-test →The company achieved FY 2025 revenue of $85.3M, cut over $40M in annualized costs, and ended with about $550M cash. Following the strategic sale of SomaLogic to Illumina, Standard BioTools entered 2026 with a streamlined business and approximately $1 billion in NOL carryforwards, providing significant flexibility for disciplined M&A.
Competitive Landscape
Pro stress-test →Standard BioTools serves academic research institutions, translational research centers, cancer centers, and biopharmaceutical/biotechnology companies. The company competes in specialized life sciences instrumentation and consumables markets for single-cell and spatial biology research.
Industry Context
Standard BioTools Inc. operates in Life Sciences Tools & Services.
Key facts
Headquarters: Boston, Massachusetts · Revenue: $85.3M · Market cap: $434.56M